IP Library › Granted Patent US 12,514,907
Granted Patent B2
US 12,514,907 · App. 18/357,666 · Granted Jan 6, 2026

Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes

Inventors: Steven Prestrelski (Chicago, IL); Brett Newswanger (Chicago, IL); Martin Cummins (Chicago, IL); Michael Riddell (Chicago, IL)
Assignee: Xeris Pharmaceuticals, Inc.
A61K38/26A61K9/0053A61K47/02A61K47/10A61K47/26A61P3/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,514,907
App. No.
18/357,666
Granted
Jan 6, 2026
Kind
B2
Abstract

Certain embodiments are directed to methods for treating, ameliorating, or preventing exercise-induced or exercise-associated hypoglycemia comprising administration to a subject in need thereof a formulation(s) of glucagon or glucagon analog in an amount effective to treat, ameliorate, or prevent the condition. The subject can be administered a glucagon or a glucagon analog composition 1, 5, 10, 15 to 20, 25, 30 minutes prior to initiation of exercise.

Claims (27)

1 . A method for treating exercise-induced hypoglycemia in a subject comprising administering a composition comprising glucagon, a glucagon analog, or salt thereof 5 to 30 minutes prior to initiation of exercise; wherein said composition is a single-phase solution comprising glucagon, a glucagon analog, or salt thereof, dissolved in an aprotic polar solvent.

2 . The method of claim 1 , wherein the subject is a diabetic subject.

3 . The method of claim 2 , wherein the diabetic subject uses exogenous insulin.

4 . The method of claim 1 , wherein the composition comprises 50 to 300 μg of glucagon, glucagon analog, or salt thereof.

5 . The method of claim 4 , wherein the composition comprises 150 μg of glucagon, glucagon analog, or salt thereof.

6 . The method of claim 1 , wherein the composition is administered as a bolus.

7 . The method of claim 1 , wherein the composition is administered as an infusion over 5 to 45 minutes.

8 . The method of claim 1 , wherein the composition is administered from a delivery apparatus, wherein the apparatus comprises: (i) a reservoir containing the glucagon, glucagon analog, or salt thereof composition; and (ii) an electronic pump configured to intradermally, subcutaneously, or intramuscularly deliver at least a portion of the composition to a subject.

9 . The method of claim 8 , wherein the delivery apparatus is a closed-loop, open-loop, or no loop system for delivering the composition to the subject.

10 . The method of claim 1 , wherein the aprotic polar solvent is DMSO.

11 . The method of claim 1 , wherein the aprotic polar solvent is a deoxygenated aprotic polar solvent.

12 . The method of claim 1 , wherein the composition further comprises an ionization stabilizing excipient, wherein (i) the glucagon, glucagon analog, or salt thereof is dissolved in the aprotic polar solvent in an amount from about 0.1 mg/mL up to the solubility limit of the glucagon, glucagon analog, or salt thereof; and (ii) the ionization stabilizing excipient is dissolved in the aprotic polar solvent in an amount sufficient to stabilize the ionization of the glucagon, glucagon analog, or salt thereof.

13 . The method of claim 12 , wherein the ionization stabilizing excipient is at a concentration of 0.1 mM to 100 mM.

14 . The method of claim 12 , wherein the ionization stabilizing excipient is a mineral acid.

15 . The method of claim 14 , wherein the mineral acid is sulfuric acid.

16 . The method of claim 14 , wherein the composition further comprises one or more sugars or starches.

17 . The method of claim 16 , wherein the sugar is trehalose, glucose, or sucrose.

18 . The method of claim 16 , wherein the composition comprises at least 80 wt. % of the aprotic polar solvent, 3 to 7 wt. % of the sugar or starch, 0.001 to 0.1 wt. % of an amphoteric molecule, and 0 wt. % to less than 0.1 wt. % of the mineral acid.

19 . The method of claim 12 , wherein the ionization stabilizing excipient is sulfuric acid and the aprotic polar solvent is DMSO.

20 . The method of claim 12 , wherein the composition has a moisture content of less than 10%, 5%, or 3%.

21 . The method of claim 12 , wherein the composition further comprises a preservative at less than 10%, 5%, or 3% w/v.

22 . The method of claim 21 , wherein the preservative is benzyl alcohol, methyl parabens, propyl parabens, or mixtures thereof.

23 . The method of claim 12 , wherein the composition further comprises a sugar alcohol at less than 10%, 5%, or 3% w/v.

24 . The method of claim 23 , wherein the sugar alcohol is mannitol or sorbitol.

25 . The method of claim 1 , wherein the composition has a water content of less than 15 wt. %, less than 3 wt. %, 3 to 10 wt. %, or 5 to 8 wt. %.

26 . The method of claim 1 , wherein the glucagon, glucagon analog, or salt thereof, has (i) been previously dried from a buffer; (ii) has a first ionization profile that corresponds to an optimal stability and solubility for the glucagon, glucagon analog, or salt thereof; (iii) is reconstituted into the aprotic polar solvent; and (iv) has a second ionization profile in the aprotic polar solvent, wherein the first and second ionization profiles are within 1 pH unit of one another.

27 . The method of claim 1 , wherein the composition has been stored in the reservoir for at least 1, 2, 3, 4, 5, 6, 7, 14, 21, 30, 45, or 60 days.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2025
From: PRESTRELSKI, STEVEN; NEWSWANGER, BRETT; CUMMINS, MARTIN; RIDDELL, MICHAEL
To: XERIS PHARMACEUTICALS, INC.
Reel/Frame 073022/0053 →
SECURITY INTEREST Recorded Mar 5, 2024
From: XERIS PHARMACEUTICALS, INC.; STRONGBRIDGE DUBLIN LTD.
To: HAYFIN SERVICES LLP
Reel/Frame 066647/0595 →
Continuity (3)
Continuation 16955698
Provisional Application 62609964 · Dec 22, 2017
Related Publication 20240016898A1 · Jan 18, 2024
References Cited (34)
US 20120232001A1 · Prestrelski et al. · 2012 [cited by applicant]
US 20140221288A1 · Prestrelski et al. · 2014 [cited by applicant]
US 20140287998A1 · Rylander, Jr. et al. · 2014 [cited by applicant]
US 20170007675A1 · Prestrelski · 2017 [cited by examiner]
US 20170202926A1 · Chen · 2017 [cited by applicant]
CN 103442695A · 2013 [cited by applicant]
CN 107106659A · 2017 [cited by applicant]
JP 2017505331A · 2017 [cited by applicant]
WO WO2015120231A2 · 2015 [cited by examiner]
WO WO2016196976A1 · 2016 [cited by applicant]
WO WO2016201248A1 · 2016 [cited by applicant]
WO WO2017053922A1 · 2017 [cited by applicant]
WO WO2019126753A1 · 2019 [cited by applicant]
Brazeau, A-S., et al., “Barriers to physical activity among patients with type 1 diabetes,” [cited by applicant]
Camacho, R.C., et al., “Glucoregulation during and after exercise in health and insulin-dependent diabetes,” [cited by applicant]
Campbell, M.D., et al., “Large pre- and postexercise rapid-acting insulin reductions preserve glycemia and prevent early-but not late-onset hypoglycemia in patients with type 1 diabetes,” [cited by applicant]
Campbell, M.D., et al., “Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial,” [cited by applicant]
Chu, L., et al., “Clinical management of the physically active patient with type 1 diabetes,” [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/067294, European Patent Office, Netherlands, mailed on Mar. 26, 2019, 11 pages. [cited by applicant]
McCall, B., “Minidose Glucagon for Exercise-Induced Hypoglycemia in TID,” MedScape.com, published on Sep. 18, 2017, accessed at https://www.medscape.com/viewarticle/885795_print, accessed on Sep. 22, 2020, 2 pages. [cited by applicant]
Oskarsson, P.R., et al., “Metabolic and hormonal responses to exercise in type 1 diabetic patients during continuous subcutaneous, as compared to continuous intraperitoneal, insulin infusion,” [cited by applicant]
Rabasa-Lhoret, R., et al., “Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regim… [cited by applicant]
Ranjan, A., “Glucagon treatment in type 1 diabetes—with focus on restoring plasma glucose during mild hypoglycemia,” [cited by applicant]
Rickels, M.R., et al., “Mini-dose Glucagon as a Novel Approach to Prevent Exercise-Induced Hypoglycemia in Type 1 Diabetes,” 77 [cited by applicant]
Riddell, M.C., et al., “Glucose ingestion matched with total carbohydrate utilization attenuates hypoglycemia during exercise in adolescents with IDDM,” [cited by applicant]
Robertson, K., et al., “ISPAD Clinical Practice Consensus Guidelines 2014 Compendium. Exercise in children and adolescents with diabetes,” [cited by applicant]
Stenerson, M., et al., “The impact of accelerometer use in exercise-associated hypoglycemia prevention in type 1 diabetes,” [cited by applicant]
Taleb, N., et al., “Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial,” [cited by applicant]
Tanenberg, R.J., et al., “Confirmation of hypoglycemia in the “dead-in-bed” syndrome, as captured by a retrospective continuous glucose monitoring system,” [cited by applicant]
Taplin, C.E., et al., “Preventing post-exercise nocturnal hypoglycemia in children with type 1 diabetes,” [cited by applicant]
Tsalikian, E., et al., “Impact of exercise on overnight glycemic control in children with type 1 diabetes mellitus,” [cited by applicant]
West, D.J., et al., “Blood glucose responses to reductions in pre-exercise rapid-acting insulin for 24 h after running in individuals with type 1 diabetes,” [cited by applicant]
Haymond, M.W. et al., “Efficacy and Safety of Mini-Dose Glucagon for Treatment of Nonsevere Hypoglycemia in Adults With Type 1 Diabetes,” [cited by applicant]
Liang, J., “Research Progress of the Relationship between Glucagon and Type 1 Diabetes,” [cited by applicant]